Search
Vistagen Therapeutics Inc
VTGNAdd to Watchlist
0.168USD
-0.003-1.75%
Close 10-30 16:00（ET）
7.46MMarket Cap
LossP/E TTM
Vistagen Therapeutics Inc (VTGN) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to Vistagen Therapeutics Inc in the past month.
Hold
0 Strong Buy
0 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
0.967USD+468.63%
VTGN Analyst Recommendation Trends
In the current month, VTGN has received 0 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. VTGN average Analyst price target in the last month is 0.967.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
5
5
5
5
5
5
VTGN Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
Financial Forecasting
Based on analysts' estimates, VTGN EPS is projected to reach -0.375 in FY2027Q2, following reported EPS of -0.303 in FY2027Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
FY2027Q3
Forecast
-0.49
-0.34
-0.37
-0.38
-0.36
Actual
-0.45
-0.38
-0.30
--
--
Surprise
+7.93%
-14.19%
+18.06%
--
--
FAQs
What is Vistagen Therapeutics Inc's expected revenue for the next quarter?
Vistagen Therapeutics Inc's expected revenue is 250.00K.
What is Vistagen Therapeutics Inc's price target?
Analysts forecast that Vistagen Therapeutics Inc's price target is USD 0.97, with the highest forecast at USD 1.00 and the lowest forecast at USD 0.90.
How have Vistagen Therapeutics IncVTGN's recent earnings per share performed?
The market expectation was USD -0.30, while Vistagen Therapeutics IncVTGN's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD -0.38.
What is the analyst rating for Vistagen Therapeutics Inc?
Based on the ratings of Vistagen Therapeutics Inc's stock from 3 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.